10 Micro-, Small-Cap Firms Were Last Week’s Top Performers

7. BioXcel Therapeutics Inc. (NASDAQ:BTAI)

BioXcel’s share price increased by 56 percent week-on-week to finish Friday at $3.37 from $2.16 on February 28 as investor sentiment was largely boosted by news that it has achieved a 33-percent enrollment for the third phase study of its BXCL501 which aims to treat agitation associated with various neuropsychiatric disorders that is affecting an estimated 23 million individuals in the US.

According to BTAI, it aims to enroll 200 patients to join the study, and it officially opened 23 clinical trial sites for the trial.

The study focuses on the lowest approved dose of IGALMI and aims to support a supplemental new drug application for label expansion in the home setting. BTAI expects to release the top-line data in the second half of the year.